EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS‐CoV‐2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4 + T‐Cell Activity

Victor H Ferreira iD, Brandon Keith iD, Faranak Mavandadnejad, Alejandro Ferro, Sara Marocco, Golnaz Amidpour, Alexandra Kurtesi, Freda Qi iD, Anne-Claude Gingras iD, Victoria G Hall iD, Deepali Kumar iD, Atul Humar iD

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Victor H Ferreira und 11 weiteren Autor:innen. Beteiligte Einrichtung: University Health Network (UHN) Ajmera Transplant Centre, Toronto General Hospital Research Institute (TGHRI), Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, CD4-Positive T-Lymphocytes, Adaptive Immunity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ajmera Transplant Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Solid organ transplant (SOT) recipients are at increased risk for severe COVID‐19 and often exhibit reduced vaccine efficacy due to chronic immunosuppression. As new SARS‐CoV‐2 variants emerge, understanding immune responses following natural infection remains critical for informing protection strategies in this vulnerable population. We conducted a longitudinal study of SOT recipients who had recovered from Omicron BA.1 or BA.2 infection, evaluating immune responses to the JN.1 subvariant at 4–6 weeks and 1 year postinfection.

Methods

Neutralizing antibodies to JN.1 were measured using a pseudovirus neutralization assay, and JN.1‐specific T‐cell responses were assessed by flow cytometry. Frequencies of bulk T‐cells and innate immune cells, identified via flow cytometry, and their correlation with adaptive responses were also analyzed.

Results

At 4–6 weeks, 30% of participants had detectable JN.1‐neutralizing antibodies, rising to 43% at one year, although titers remained low. In contrast, CD4⁺ T‐cell responses were robust and detected in 75%–83% of participants at 4–6 weeks, increasing to 75%–93% by 1 year. CD8⁺ T‐cell responses were observed less frequently. Exploratory correlations between innate and bulk T‐cell subsets with heterologous adaptive immune responses were investigated but did not reveal statistically significant relationships.

Conclusion

These findings offer important insights into the durability and breadth of immunity following natural infection in immunocompromised transplant recipients. While heterologous neutralizing antibodies were limited, sustained CD4 + T‐cell responses may help mitigate severe disease following exposure to JN.1‐derived variants, which continue to dominate the SARS‐CoV‐2 landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19CD4-Positive T-LymphocytesAdaptive ImmunityOrgan TransplantationHumansMaleFemaleMiddle AgedLongitudinal StudiesAntibodies, NeutralizingImmunity, InnateTransplant RecipientsAdultAntibodies, ViralAgedImmunity, HeterologousImmunocompromised HostNeutralization Tests

Stichwörter der Autor:innen

COVID‐19JN.1Neutralizing antibodiesOmicron JN.1 subvariantSARS‐CoV‐2T‐cellshumoral immunityinnate immunityorgan transplantationtransplant recipients

Substanzen

Antibodies, NeutralizingAntibodies, Viral

Autor:innen und Institutionen

  • University Health Network (UHN) Ajmera Transplant Centre, Toronto General Hospital Research Institute (TGHRI), Toronto, Ontario, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Victor H Ferreira, Brandon Keith, Freda Qi, Anne-Claude Gingras, Victoria G Hall, Deepali Kumar, Atul Humar

Förderung

  • Ajmera Transplant Centre

Zitieren

APA

Ferreira, V. H., Keith, B., Mavandadnejad, F., Ferro, A., Marocco, S., Amidpour, G., Kurtesi, A., Qi, F., Gingras, A. C., Hall, V. G., Kumar, D., & Humar, A. (2025). Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS‐CoV‐2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4 + T‐Cell Activity. Transplant Infectious Disease. https://doi.org/10.1111/tid.70067

Vancouver

Ferreira VH, Keith B, Mavandadnejad F, Ferro A, Marocco S, Amidpour G, et al. Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS‐CoV‐2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4 + T‐Cell Activity. Transplant Infectious Disease. 2025. doi:10.1111/tid.70067

BibTeX
@article{Ferreira2025,
  author = {Ferreira, Victor H and Keith, Brandon and Mavandadnejad, Faranak and Ferro, Alejandro and Marocco, Sara and Amidpour, Golnaz and Kurtesi, Alexandra and Qi, Freda and Gingras, Anne-Claude and Hall, Victoria G and Kumar, Deepali and Humar, Atul},
  title = {Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS‐CoV‐2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4 + T‐Cell Activity},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70067}
}
Kostenlos starten →